title: Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis.
abstract: BACKGROUND
  Amplification of DNA in certain chromosomal regions plays a crucial role in the development and progression of human malignancies, specifically when protooncogenic target genes within those amplicons are overexpressed. Comparative genomic hybridization studies have revealed frequent amplification at 20q in primary breast tumors. The aim of the current study was to identify specific genes in the 20q amplicon that were likely to have clinical significance.
  
  
  METHODS
  The authors examined 38 primary breast tumors by using a quantitative real-time reverse transcription-polymerase chain reaction assay to determine expression levels of 18 potential targets for amplification events involving 20q. Potential correlations between elevated expression of the genes in question and clinicopathologic parameters or clinical outcomes were analyzed.
  
  
  RESULTS
  Elevated expression of NABC1 was significantly associated with positive estrogen (P < 0.001) and progesterone (P = 0.027) receptors in breast tumors, and high expression of PTK6 was significantly correlated with positive estrogen receptor status (P = 0.022) and postmenopausal status (P = 0.008). Patients whose tumors showed elevated expression of NCOA3 (AIB1) had significantly shorter disease-free (P = 0.017) and overall (P = 0.0021) survival times after surgery than did other patients with breast tumors. Reduced disease-free survival, but not reduced overall survival, was associated with high expression of TOP1 (P = 0.035) and TFAP2C (P = 0.035).
  
  
  CONCLUSIONS
  TOP1, TFAP2C, and (particularly) NCOA3 may be prognostic indicators for patients with breast tumors.
authors.affiliation: Department of Molecular Cytogenetics, Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan.
authors.forename: Chen
authors.initials: C
authors.lastname: Zhao
authors.forename: Kohichiroh
authors.initials: K
authors.lastname: Yasui
authors.forename: Chol Joo
authors.initials: CJ
authors.lastname: Lee
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kurioka
authors.forename: Youhei
authors.initials: Y
authors.lastname: Hosokawa
authors.forename: Takahiro
authors.initials: T
authors.lastname: Oka
authors.forename: Johji
authors.initials: J
authors.lastname: Inazawa
mesh_terms: D000123:Acetyltransferases; D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism; D018270:Carcinoma, Ductal, Breast / Q000235:genetics* / Q000378:metabolism; D004264:DNA Topoisomerases, Type I / Q000235:genetics* / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000235:genetics*; D005260:Female; D015870:Gene Expression; D051548:Histone Acetyltransferases; D006801:Humans; D008875:Middle Aged; D056921:Nuclear Receptor Coactivator 3; D015513:Oncogene Proteins; D011379:Prognosis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016019:Survival Analysis; D015534:Trans-Activators / Q000235:genetics*; D050656:Transcription Factor AP-2; D014157:Transcription Factors / Q000235:genetics*
chemical_list: D004268:DNA-Binding Proteins; D015513:Oncogene Proteins; C493679:TFAP2C protein, human; D015534:Trans-Activators; D050656:Transcription Factor AP-2; D014157:Transcription Factors; D000123:Acetyltransferases; D051548:Histone Acetyltransferases; C538866:NCOA3 protein, human; D056921:Nuclear Receptor Coactivator 3; D004264:DNA Topoisomerases, Type I